Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
CJC-1295 with DAC | Research Peptide
CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH 1–29), chemically modified through conjugation with a Drug Affinity Complex (DAC). The DAC component contains a reactive linker designed to form a covalent association with serum albumin in experimental systems, significantly extending the peptide's systemic persistence compared to unmodified GHRH analogues. This bioconjugation alters pharmacokinetic behaviour while preserving the core peptide sequence responsible for receptor binding and activation.
In research settings, CJC-1295 with DAC is studied for its interaction with GHRH receptors on pituitary-derived cells, and the downstream signalling cascades this initiates. It is particularly valuable in models examining prolonged receptor engagement and extended endocrine pathway responses, where a short-acting compound would be unsuitable.
Research Applications
CJC-1295 with DAC is used as a molecular probe across a range of endocrinology and peptide signalling research contexts, including studies into GHRH receptor binding and activation dynamics, growth hormone axis signalling, endocrine feedback mechanisms, and the downstream transcriptional responses associated with extended peptide-receptor interaction. Its albumin-binding properties make it particularly suited to experimental models where prolonged GHRH receptor stimulation is required.
Reconstitution
Reconstitute in sterile water or a suitable buffered aqueous solution under dry conditions — the peptide is hygroscopic and should be handled accordingly. Due to the DAC conjugation, mix especially gently and avoid any vigorous agitation. Filter sterilise through a 0.22 µm membrane if required. Inspect the solution for precipitation or changes in clarity before use in sensitive assays. Once reconstituted, aliquot into single-use volumes and store at −20°C or below. Avoid repeated freeze-thaw cycles to preserve peptide integrity.
Additional Notes
CJC-1295 with DAC has appeared in anti-doping and forensic literature; this classification relates to sporting regulation and is unrelated to its use as a laboratory research compound. This peptide was previously evaluated in clinical research settings; development was discontinued for reasons unrelated to peptide-specific toxicity findings.
Important Notice
All products supplied by Perfect Profile Peptides are intended strictly for in vitro and laboratory research use only. They are not suitable for human or veterinary administration and should be handled in accordance with standard laboratory safety protocols.
CJC-1295 with DAC | Research Peptide
CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH 1–29), chemically modified through conjugation with a Drug Affinity Complex (DAC). The DAC component contains a reactive linker designed to form a covalent association with serum albumin in experimental systems, significantly extending the peptide's systemic persistence compared to unmodified GHRH analogues. This bioconjugation alters pharmacokinetic behaviour while preserving the core peptide sequence responsible for receptor binding and activation.
In research settings, CJC-1295 with DAC is studied for its interaction with GHRH receptors on pituitary-derived cells, and the downstream signalling cascades this initiates. It is particularly valuable in models examining prolonged receptor engagement and extended endocrine pathway responses, where a short-acting compound would be unsuitable.
Research Applications
CJC-1295 with DAC is used as a molecular probe across a range of endocrinology and peptide signalling research contexts, including studies into GHRH receptor binding and activation dynamics, growth hormone axis signalling, endocrine feedback mechanisms, and the downstream transcriptional responses associated with extended peptide-receptor interaction. Its albumin-binding properties make it particularly suited to experimental models where prolonged GHRH receptor stimulation is required.
Reconstitution
Reconstitute in sterile water or a suitable buffered aqueous solution under dry conditions — the peptide is hygroscopic and should be handled accordingly. Due to the DAC conjugation, mix especially gently and avoid any vigorous agitation. Filter sterilise through a 0.22 µm membrane if required. Inspect the solution for precipitation or changes in clarity before use in sensitive assays. Once reconstituted, aliquot into single-use volumes and store at −20°C or below. Avoid repeated freeze-thaw cycles to preserve peptide integrity.
Additional Notes
CJC-1295 with DAC has appeared in anti-doping and forensic literature; this classification relates to sporting regulation and is unrelated to its use as a laboratory research compound. This peptide was previously evaluated in clinical research settings; development was discontinued for reasons unrelated to peptide-specific toxicity findings.
Important Notice
All products supplied by Perfect Profile Peptides are intended strictly for in vitro and laboratory research use only. They are not suitable for human or veterinary administration and should be handled in accordance with standard laboratory safety protocols.